跳至主要内容
临床试验/CTRI/2023/07/054679
CTRI/2023/07/054679尚未招募Unknown

COMPARISON OF EFFICACY & SAFETY OF TWO FRONTLINE CYTOTOXIC CHEMOTHERAPY REGIMENS IN NEWLY DIAGNOSED CANCER OF BILIARY TRACT:A PROSPECTIVE RANDOMIZED CONTROL CONTROL STUDY

O SPONSOR0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
Unknown
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Age >=18 years
  • 2.ECOG performance status 0,1,2,3
  • 3.Histologically confirmed biliary tract cancer.
  • 4.Radiologically confirmed unresectable or metastatic disease.
  • 5.Patient with Haemoglobin level more than 9%
  • 6.Patient with platelet count more than 100,000
  • 7.Patient with serum Bilirubin level less than 5gm/dl
  • 8.Patients with mild to moderate grade transaminitis, SGOT and SGPT level less than 3X of UNL
  • 9.Estimated GFR more than 45 mL/min as measured by the Cockcroft-Gault method14
  • 10.Left ventricular ejection fraction >=40%
  • 11.Chemotherapy naïve patients

排除标准

  • 1. Age less than 18 years
  • 2. End-stage kidney disease requiring haemodialysis
  • 3. New York Heart Association grade III or IV congestive heart failure, or history of unstable angina/ myocardial infarction within six months prior to study entry
  • 4.Grade 2 or worse peripheral neuropathy
  • 5.Serum SGOT/SGPT levels >5 times the upper normal limits (UNL) provided, Serum Bilirubin (Total) >3 times the UNL.
  • 6.Any acquired immunodeficiency state
  • 7.Presence of second malignancy
  • 8. Pregnant or Lactating females.
  • 9.Surgically resectable tumors
  • 10. Active infections

研究者

发起方
O SPONSOR

相似试验